A New Strategy for Adult T-Cell Leukemia Treatment Targeting Glycogen Synthase Kinase-3β

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1).
• The role of glycogen synthase kinase-3 beta (GSK-3β) in ATL pathogenesis is complex and not fully understood.
• GSK-3β is a kinase involved in various cellular processes, including cell survival and proliferation.

Purpose of the Study:

• To investigate the specific role of GSK-3β in HTLV-1-induced ATL.
• To evaluate the potential of targeting GSK-3β as a therapeutic strategy for ATL.

Main Methods:

• Analysis of GSK-3β expression and localization in HTLV-1-infected T-cells.
• Assessment of cell proliferation, survival, cell cycle, and apoptosis using various assays (WST-8, flow cytometry, Hoechst staining).
• Evaluation of protein expression related to cell cycle, apoptosis, and survival signaling pathways via RT-PCR, immunofluorescence, and immunoblotting.
• Inhibition of GSK-3β using specific inhibitors (9-ING-41, LY2090314) and genetic knockdown.

Main Results:

• Nuclear accumulation of GSK-3β was observed in HTLV-1-infected T-cells.
• GSK-3β inhibition or knockdown suppressed ATL cell proliferation and survival.
• GSK-3β inhibition induced G2/M cell cycle arrest, caspase-mediated apoptosis, ferroptosis, and necroptosis.
• Inhibitors affected key signaling pathways, including JNK, NF-κB, Akt, and STAT, and increased reactive oxygen species (ROS).

Conclusions:

• GSK-3β functions as an oncogene in ATL.
• Targeting GSK-3β represents a promising therapeutic avenue for ATL treatment.